Unicycive Therapeutics, Inc. (UNCY) fundamentals score
kidney disease, an area Unicycive Therapeutics believes we have the potential to offer medical benefit. Its initial focus is on developing drugs and getting
Pharmaceutical Preparations · Healthcare · Listed on NASDAQ
Overall: 3.1 out of 10, Unhealthy fundamentals
- Growth: 3.5/10
- Profitability: 1.0/10
- Financial health: 3.4/10
- Earnings quality: 7.0/10
- Valuation: 1.5/10
Scores are calculated from Unicycive Therapeutics, Inc.’s SEC filings, using the 12 months through 2023-12. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10